BLFS Nasdaq Health Care Supplies Financials FY2016–FY2025
BioLife Solutions had $96.2M of revenue in fiscal 2025, up 28.9% on the year before. Over five years, revenue changed +14.9% a year on average.
Hi! I read BioLife Solutions’s latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+28.9%
Yes. Sales grew 28.9% last year.
Does it make a profit?
−4.8%
No. It lost money last year.
Does profit turn into cash?
11.1%
Yes. 11.1% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. BioLife Solutions' operating loss in 2025 leaves its earnings before interest, tax, depreciation and amortization negative, so net debt to EBITDA is blank for that year.
Is it selling more, and how much does it keep?
KIRA · BioLife Solutions had $96.2M of revenue in fiscal 2025, up 28.9% on the year before. Over five years, revenue changed +14.9% a year on average. Its operating margin was −17.3%, down 11.3 pts: of every 100 in sales, about −17 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA · BioLife Solutions lost $4.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA · Free cash flow was $10.6M in fiscal 2025, 11.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA · BioLife Solutions returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 5.6%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA · In the last 12 months, insiders sold $34.0M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$34.0M
9 insiders
Of sales under plans
1%
$0.3M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 21, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sold | 650,000 | $23.70 | $15.4M | Form 4 |
| May 20, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sold | 250,000 | $23.70 | $5.9M | Form 4 |
| May 19, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sold | 300,000 | $22.65 | $6.8M | Form 4 |
| Mar 23, 2026 | Karen A. FosterChief Quality and Operations | Sold plan | 2,577 | $19.17 | $0.0M | Form 4 |
| Mar 9, 2026 | Karen A. FosterChief Quality and Operations | Sold | 500 | $20.00 | $0.0M | Form 4 |
| Mar 5, 2026 | Karen A. FosterChief Quality and Operations | Sold | 96,923 | $20.15 | $2.0M | Form 4 |
| Mar 3, 2026 | Troy WichtermanChief Financial Officer | Sold plan | 588 | $20.74 | $0.0M | Form 4 |
| Mar 3, 2026 | Sarah AebersoldChief Human Resources Officer | Sold plan | 219 | $20.74 | $0.0M | Form 4 |
| Mar 3, 2026 | Aby J. MathewEVP & Chief Scientific Officer | Sold plan | 529 | $20.74 | $0.0M | Form 4 |
| Mar 3, 2026 | Sean WernerChief Technology Officer | Sold plan | 111 | $20.74 | $0.0M | Form 4 |
| Mar 3, 2026 | Karen A. FosterChief Quality and Operations | Sold plan | 418 | $20.74 | $0.0M | Form 4 |
| Mar 3, 2026 | Todd BerardChief Marketing Officer | Sold plan | 353 | $20.74 | $0.0M | Form 4 |
| Jan 6, 2026 | Todd BerardChief Marketing Officer | Sold plan | 344 | $25.59 | $0.0M | Form 4 |
| Jan 6, 2026 | Sarah AebersoldChief Human Resources Officer | Sold plan | 241 | $25.59 | $0.0M | Form 4 |
| Jan 6, 2026 | Karen A. FosterChief Quality and Operations | Sold plan | 335 | $25.59 | $0.0M | Form 4 |
| Jan 6, 2026 | Troy WichtermanChief Financial Officer | Sold plan | 990 | $25.59 | $0.0M | Form 4 |
| Jan 6, 2026 | Aby J. MathewEVP & Chief Scientific Officer | Sold plan | 405 | $25.59 | $0.0M | Form 4 |
| Dec 15, 2025 | Amy DuRossDirector | Sold | 2,000 | $24.60 | $0.0M | Form 4 |
| Dec 15, 2025 | Sarah AebersoldChief Human Resources Officer | Sold plan | 713 | $24.46 | $0.0M | Form 4 |
| Dec 9, 2025 | Todd BerardChief Marketing Officer | Sold plan | 358 | $25.13 | $0.0M | Form 4 |
| Dec 9, 2025 | Karen A. FosterChief Quality and Operations | Sold plan | 519 | $25.13 | $0.0M | Form 4 |
| Dec 9, 2025 | Troy WichtermanChief Financial Officer | Sold plan | 1,033 | $25.13 | $0.0M | Form 4 |
| Dec 9, 2025 | Aby J. MathewEVP & Chief Scientific Officer | Sold plan | 631 | $25.13 | $0.0M | Form 4 |
| Dec 9, 2025 | Sarah AebersoldChief Human Resources Officer | Sold plan | 233 | $25.13 | $0.0M | Form 4 |
| Dec 4, 2025 | Troy WichtermanChief Financial Officer | Sold | 30,000 | $25.72 | $0.8M | Form 4 |
| Nov 26, 2025 | Amy DuRossDirector | Sold | 2,000 | $27.00 | $0.1M | Form 4 |
| Nov 25, 2025 | Aby J. MathewEVP & Chief Scientific Officer | Sold plan | 526 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Todd BerardChief Marketing Officer | Sold plan | 351 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Troy WichtermanChief Financial Officer | Sold plan | 584 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Sean WernerChief Technology Officer | Sold plan | 110 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Karen A. FosterChief Quality and Operations | Sold plan | 415 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Sarah AebersoldChief Human Resources Officer | Sold plan | 217 | $26.74 | $0.0M | Form 4 |
| Nov 25, 2025 | Amy DuRossDirector | Sold | 2,000 | $27.00 | $0.1M | Form 4 |
| Nov 21, 2025 | Amy DuRossDirector | Sold | 1,000 | $26.00 | $0.0M | Form 4 |
| Nov 20, 2025 | Amy DuRossDirector | Sold | 4,523 | $24.51 | $0.1M | Form 4 |
| Nov 19, 2025 | Amy DuRossDirector | Sold | 477 | $24.50 | $0.0M | Form 4 |
| Nov 13, 2025 | Roderick De GreefPresident and CEO, Director | Sold | 31,165 | $25.33 | $0.8M | Form 4 |
| Nov 12, 2025 | Roderick De GreefPresident and CEO, Director | Sold | 33,418 | $25.88 | $0.9M | Form 4 |
| Nov 11, 2025 | Roderick De GreefPresident and CEO, Director | Sold | 35,417 | $26.15 | $0.9M | Form 4 |
| Oct 24, 2025 | Joydeep GoswamiDirector | Sold plan | 1,666 | $28.99 | $0.0M | Form 4 |
| Oct 22, 2025 | Roderick De GreefPresident and CEO, Director | Sold plan | 37,795 | $27.30 | $1.0M | Form 4 |
| Oct 20, 2025 | Sean WernerChief Technology Officer | Sold plan | 275 | $27.82 | $0.0M | Form 4 |
| Oct 15, 2025 | Casdin Partners GP, LLC10% owner | Sold | 750,000 | $28.55 | $21.4M | Form 4 |
| Oct 9, 2025 | Karen A. FosterChief Quality and Operations | Sold plan | 419 | $27.36 | $0.0M | Form 4 |
| Oct 9, 2025 | Aby J. MathewEVP & Chief Scientific Officer | Sold plan | 509 | $27.36 | $0.0M | Form 4 |
| Oct 9, 2025 | Troy WichtermanChief Financial Officer | Sold plan | 833 | $27.36 | $0.0M | Form 4 |
| Oct 9, 2025 | Todd BerardChief Marketing Officer | Sold plan | 289 | $27.36 | $0.0M | Form 4 |
| Oct 9, 2025 | Sarah AebersoldChief Human Resources Officer | Sold plan | 188 | $27.36 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA · BioLife Solutions has $83.9M more cash than debt.
Cash, debt and the ratios that show how comfortably BioLife Solutions can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $69.9M | $62.7M | $44.2M | $101M | $88.9M |
| Debt incl. finance leases | $7.7M | $25.9M | $25.4M | $15.9M | $5.0M |
| Net debt / EBITDA | — | −43.2x | — | −124.2x | — |
| Debt / equity | 0.0x | 0.1x | 0.1x | 0.1x | 0.0x |
| Interest coverage | −77.8x | −10.1x | −8.9x | −2.8x | −21.8x |
| Current ratio | 3.0x | 3.1x | 2.9x | 4.5x | 5.9x |
| Quick ratio | 2.3x | 2.3x | 2.2x | 3.7x | 4.6x |
| Total assets | $554M | $450M | $413M | $400M | $406M |
| Total liabilities | $76.2M | $86.0M | $75.1M | $50.6M | $34.0M |
| Shareholders' equity | $478M | $364M | $338M | $349M | $372M |
| Net debt (− = net cash) | −$62.2M | −$36.8M | −$18.8M | −$84.8M | −$83.9M |
KIRA · Its return on capital was −4.8%: every 100 invested in the business earned about −5 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA · BioLife Solutions passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✓ | ✓ |
| Return on assets rose | ✓ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | ✕ | ✓ | ✓ |
| Current ratio rose | ✕ | ✓ | ✓ |
| Share count didn't rise | ✕ | ✕ | ✕ |
| Gross margin rose | — | ✓ | ✕ |
| Revenue rose relative to assets | ✓ | ✓ | ✓ |
| F-score | 3 / 8 | 7 / 9 | 6 / 9 |
| Accruals ratio | −12.9% | −7.1% | −6.1% |
| Altman Z'' | 3.20 | 6.34 | 10.32 |
What does the share cost, and how does it compare?
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
—
Adds net cash of $83.9M and divides by 48.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
—
Reference multiples: today — · peers 49.0x · sector 28.1x.
KIRA · BioLife Solutions grew sales faster than 4 of its 4 similar companies.
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| BioLife Solutions BLFS | — | 28.9% | −17.3% | 11.1% | −4.8% | — | 6 | |
| Haemonetics HAE | $5.4B | −2.0% | 11.8% | 19.5% | 6.7% | 57.3x | 7 | Compare → |
| Lantheus LNTH | $6.7B | 0.5% | 20.2% | 23.0% | 22.7% | 24.2x | 5 | Compare → |
| ICU Medical ICUI | $4.1B | −6.3% | 1.9% | 4.1% | 0.7% | 139.5x | 6 | Compare → |
| Envista NVST | $3.9B | 8.3% | 8.0% | 8.5% | 3.2% | 40.8x | 7 | Compare → |
Every number, year by year.
Amounts in USD. Hover a ratio’s name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $8.2M | $11.0M | $19.7M | $27.4M | $48.1M | $119M | $76.2M | $68.0M | $74.6M | $96.2M |
| Gross profit | $4.8M | $6.7M | $13.5M | $18.6M | — | — | — | $41.3M | $50.1M | $62.1M |
| Research and development | $2.0M | $1.2M | $1.3M | $3.2M | $6.7M | $11.8M | $8.7M | $5.5M | $4.8M | $7.6M |
| Operating income | −$4.9M | −$1.1M | $3.7M | −$0.2M | −$6.2M | −$35.2M | −$5.9M | −$17.2M | −$4.5M | −$16.6M |
| Interest expense | $0.1M | $0.2M | $0.0M | $0.0M | $0.0M | $0.5M | $0.6M | $1.9M | $1.6M | $0.8M |
| Pretax income | −$6.9M | −$2.5M | −$25.0M | −$3.2M | −$1.3M | −$29.0M | −$4.8M | −$12.2M | −$8.8M | −$12.1M |
| Income tax | $0.0M | $0.0M | — | −$1.5M | −$3.3M | −$20.1M | −$5.2M | −$0.1M | $0.0M | $0.0M |
| Net income | −$6.9M | −$2.5M | −$25.0M | −$1.7M | $2.0M | −$8.9M | −$140M | −$68.0M | −$20.2M | −$4.6M |
| Diluted EPS | −$0.54 | −$0.21 | −$1.56 | −$0.09 | −$0.06 | −$0.23 | −$3.25 | −$1.55 | −$0.44 | −$0.10 |
| Diluted shares | 0.01B | 0.01B | 0.02B | 0.02B | 0.03B | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | −$4.3M | $0.6M | $2.3M | $1.2M | $6.6M | −$4.6M | −$8.5M | −$12.5M | $8.4M | $20.1M |
| Capital expenditure | $0.1M | $0.1M | $0.5M | $0.7M | $2.0M | $8.4M | $10.4M | $6.4M | $3.2M | $9.5M |
| Free cash flow | −$4.5M | $0.5M | $1.9M | $0.5M | $4.7M | −$13.0M | −$18.9M | −$18.9M | $5.2M | $10.6M |
| Depreciation and amortization | $0.4M | $0.3M | $0.3M | $0.7M | $2.0M | $4.7M | $6.8M | $7.1M | $5.2M | $2.3M |
| Stock-based compensation | $0.8M | $1.3M | $1.5M | $3.0M | $6.0M | $14.0M | $25.3M | $33.2M | $30.9M | $23.0M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $14.9M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.4M | $6.7M | $30.7M | $6.4M | $90.4M | $69.9M | $62.7M | $44.2M | $101M | $88.9M |
| Total debt | $4.2M | — | — | $0.0M | $1.3M | $7.2M | $25.6M | $23.8M | $15.9M | $5.0M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.4M | $0.3M | $1.5M | $0.0M | $0.0M |
| Current assets | $4.6M | $9.9M | $37.6M | $24.1M | $115M | $126M | $139M | $121M | $149M | $137M |
| Current liabilities | $1.1M | $1.5M | $1.9M | $7.7M | $15.6M | $42.7M | $44.6M | $42.2M | $32.7M | $23.0M |
| Inventory | $1.8M | $1.8M | $3.5M | $11.0M | $11.6M | $28.3M | $34.9M | $27.2M | $29.0M | $30.2M |
| Property and equipment, net | $1.2M | $1.1M | $1.3M | $5.6M | $10.1M | $17.7M | $23.6M | $5.7M | $6.0M | $14.7M |
| Total assets | $7.9M | $12.1M | $45.5M | $92.8M | $235M | $554M | $450M | $413M | $400M | $406M |
| Total liabilities | $4.8M | $2.1M | $30.8M | $49.4M | $29.6M | $76.2M | $86.0M | $75.1M | $50.6M | $34.0M |
| Shareholders' equity | $3.2M | −$9.5M | $14.6M | $43.3M | $204M | $478M | $364M | $338M | $349M | $372M |
| Margins | ||||||||||
| Gross margin | 58.1% | 61.2% | 68.5% | 68.0% | — | — | — | 60.8% | 67.1% | 64.6% |
| Operating margin | −59.0% | −9.6% | 18.6% | −0.8% | −13.0% | −29.5% | −7.8% | −25.3% | −6.0% | −17.3% |
| EBITDA margin | −54.5% | −6.5% | 20.3% | 1.8% | −8.8% | −25.6% | 1.1% | −14.8% | 0.9% | −14.9% |
| Net margin | −83.6% | −22.8% | −126.7% | −6.1% | 4.1% | −7.5% | −183.4% | −100.0% | −27.0% | −4.8% |
| FCF margin | −54.3% | 4.2% | 9.4% | 2.0% | 9.7% | −10.9% | −24.8% | −27.8% | 7.0% | 11.1% |
| Returns | ||||||||||
| Return on capital | — | — | — | — | −6.5% | −10.5% | −1.3% | −4.2% | −1.2% | −4.8% |
| Return on capital employed | −55.7% | −12.1% | 13.5% | −0.3% | −4.1% | −9.6% | −1.3% | −4.4% | −1.2% | −4.4% |
| Return on equity | −117.8% | — | −980.6% | −5.7% | 1.6% | −2.6% | −33.2% | −19.4% | −5.9% | −1.3% |
| Return on assets | −67.8% | −25.1% | −86.8% | −2.4% | 1.2% | −2.3% | −27.8% | −15.8% | −5.0% | −1.1% |
| Growth | ||||||||||
| Revenue growth | 27.6% | 34.0% | 79.1% | 38.6% | 75.7% | 147.8% | −36.0% | −10.8% | 9.8% | 28.9% |
| Net income growth | — | — | — | — | — | −549.2% | — | — | — | — |
| FCF growth | — | — | 300.9% | −70.9% | 770.6% | −377.1% | — | — | — | 104.4% |
| Share count change | 3.8% | 4.9% | 63.1% | −10.0% | 40.3% | 41.0% | 11.9% | 1.5% | 5.4% | 5.6% |
| Financial health | ||||||||||
| Net debt / EBITDA | — | — | — | −12.9x | — | — | −43.2x | — | −124.2x | — |
| Debt / equity | 1.3x | — | — | 0.0x | 0.0x | 0.0x | 0.1x | 0.1x | 0.1x | 0.0x |
| Interest coverage | −48.5x | −5.6x | 732.4x | −44.0x | — | −77.8x | −10.1x | −8.9x | −2.8x | −21.8x |
| Current ratio | 4.1x | 6.6x | 19.4x | 3.1x | 7.4x | 3.0x | 3.1x | 2.9x | 4.5x | 5.9x |
| Quick ratio | 2.5x | 5.3x | 17.6x | 1.7x | 6.6x | 2.3x | 2.3x | 2.2x | 3.7x | 4.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.7% | 1.3% | 2.5% | 2.5% | 4.1% | 7.0% | 13.6% | 9.4% | 4.3% | 9.9% |
| Stock comp / revenue | 9.4% | 11.5% | 7.7% | 11.1% | 12.4% | 11.7% | 33.2% | 48.9% | 41.4% | 23.9% |
| Payouts / FCF | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | — | — | — | — | 5.0 | 1.0 | 2.0 | 3.0 | 7.0 | 6.0 |
| Altman Z'' | −29.8 | −10.7 | −0.9 | 5.6 | 8.5 | 6.5 | 3.9 | 3.2 | 6.3 | 10.3 |
| Accruals ratio | −25.1% | −31.1% | −95.0% | −4.2% | −2.9% | −1.1% | −26.2% | −12.9% | −7.1% | −6.1% |
Source: SEC EDGAR XBRL filings (CIK 0000834365). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
